Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial. Issue 8 (19th July 2022)

• Record Type: Journal Article
• Authors: Freedman, Benjamin L.; Berg, David D.; Scirica, Benjamin M.; Bohula, Erin A.; Goodrich, Erica L.; Sabatine, Marc S.; Morrow, David A.; Bonaca, Marc P.
• Is Part Of: Clinical cardiology. Volume 45:Issue 8(2022)
• Page Start: 831
• Page End: 838
• Publication Date: 2022-07-19
• Subjects: diabetes -- heart failure -- polyvascular disease -- risk factors -- stable atherosclerosis -- TIMI risk score for secondary prevention -- vorapaxar; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.23843
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract: Background: Heart failure (HF) is a growing public health problem and ischemic heart disease is an important risk factor. Understanding the epidemiology of HF in patients with atherosclerosis may help identify subgroups at greater risk who have the potential to derive greater benefit from preventive strategies. Methods and Results: The TRA 2°P‐TIMI 50 trial randomized 26, 449 patients with stable atherosclerosis to the antiplatelet agent vorapaxar versus placebo. Hospitalization for HF (HHF) endpoints were adjudicated from serious adverse events by blinded structured review using established definitions. HHF incidence was estimated using Kaplan–Meier analysis. Independent predictors of HHF risk were identified using multivariable logistic regression. The effect of vorapaxar on HHF risk was explored using Cox regression. The estimated incidence of HHF at 3 years was 1.6%. Independent predictors of HHF included prior HF (adjusted odds ratio [adj‐OR]: 8.31; 95% confidence interval [CI]: 6.56–10.54), age (adj‐OR [per 10 years]: 1.67; 95% CI: 1.47–1.89), type 2 diabetes mellitus (T2DM; adj‐OR: 2.55; 95% CI: 2.01–3.24), polyvascular disease (two‐territory disease, adj‐OR: 1.89; 95% CI: 1.46–2.44; three‐territory disease, adj‐OR: 2.68; 95% CI: 1.94–3.70), chronic kidney disease (CKD; adj‐OR: 1.65; 95% CI: 1.30–2.11), body mass index (BMI; adj‐OR [per 5 kg/m 2 ]: 1.15; 95% CI: 1.03–1.27), prior myocardial infarction (MI) (adj‐OR: 1.35; 95% CI: 1.03–1.78), and hypertension (adj‐OR: 1.44; 95% CI: 1.02–2.04). Patients who experienced HHF during follow‐up had higher rates of subsequent rehospitalization and death. Vorapaxar did not modify the risk of HHF. Conclusions: In patients with stable atherosclerosis, prior HF, age, T2DM, polyvascular disease, CKD, BMI, prior MI, and hypertension are important predictors of HHF risk.